The application of modeling and simulation techniques is increasingly common in the preclinical stages of the drug development process.
Introduction
Inhibitor of apoptosis (IAP) proteins are involved in the regulation of programmed cell death or apoptosis and were first identified in baculoviruses where they serve to suppress host cell death responses during viral infection (Flygare and Fairbrother 2010; Varfolomeev and Vucic 2011) . IAP proteins suppress apoptosis, in part, by inhibiting activated cytosolic cysteine/aspartate-specific proteases (caspases) that are critical for its execution (Flygare and Fairbrother 2010; Varfolomeev and Vucic 2011) . The mammalian family of IAP proteins includes X-linked IAP (XIAP), cellular IAP 1 and 2 (cIAP1 and cIAP2), and melanoma IAP (ML-IAP). Of these, only XIAP directly inhibits effector caspase-3 and caspase-7, which execute the apoptotic death program. XIAP also indirectly inhibits effector-caspase activity via inhibition of the initiator caspase-9. ML-IAP and cIAPs directly antagonize second mitochondria-derived activator of caspase/direct IAP-binding protein with low isoelectric point, pI (Smac/DIABLO), an endogenous IAP antagonist that acts by blocking XIAP-mediated inhibition of caspases. The cIAP proteins have an additional role of preventing tumor necrosis factor a (TNF-a)-mediated activation of initiator caspase-8, thereby stopping downstream activation of effector caspase-3 and caspase-7. Finally, the cIAP proteins positively regulate dx.doi.org/10.1124/dmd.113.053926.
ABBREVIATIONS: AUC 0-24 , area under the concentration-time curve from 0-24 hours; AUC inf , area under the concentration-time curve from zero to infinity; cIAP, cellular inhibitor of apoptosis; CL, plasma clearance; C max , highest observed plasma concentration; DMSO, dimethylsulfoxide; GDC-0152, (
S)-1-[(S)-2-cyclohexyl-2-([S]-2-[methylamino]propanamido)acetyl]; GDC-0917, (S)-1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)-N-
(2-(oxazol-2-yl)-4-phenylthiazol-5-yl)pyrrolidine-2-carboxamide; IAP, inhibitor of apoptosis; I, cIAP level expressed as a percentage of the DMSO control; I max , the maximum value of I; IC 50 , GDC-0917 concentration where I is 50% of I max ; k ng , net growth rate constant; K, rate constant describing the antitumor effect of GDC-0917; K max , maximum value of K; KC 50 , GDC-0917 concentration where K is 50% of K max ; LC-MS/MS, liquid chromatography with tandem mass spectrometry; ML-IAP, melanoma inhibitor of apoptosis; PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PD, pharmacodynamic; PK, pharmacokinetic; t max , time at which C max occurred; V ss , volume of distribution at steady state; XIAP, X-linked inhibitor of apoptosis.
canonical and negatively regulate noncanonical nuclear factor kB (NF-kB) signaling and induction of NF-kB target genes, including TNF-a.
Frequently, IAP proteins are overexpressed in cancer cells where they act as regulators of cancer cell survival and are often indicators of poor prognosis (Vucic and Fairbrother, 2007) . Inhibition of IAP proteins has been shown to sensitize cancer cells to proapoptotic anticancer agents. Therefore, the development of IAP antagonists as potential anticancer agents has been of interest.
Mathematic modeling and simulation, and the "learn-and-confirm paradigm," (Sheiner, 1997 ) have been applied widely in later stages of the drug development process, largely with data from clinical trials (Chien et al., 2005) . The learn-and-confirm paradigm involves the use of mathematic models to integrate information in order to "learn" about a drug candidate, but at the same time to continuously "confirm" model assumptions as new information is generated during the course of the drug development process. The net result of successive iterations of learning and confirming is an overall better understanding of a drug candidate's pharmacologic behavior.
The application of modeling and simulation techniques has been rapidly increasing in the preclinical drug discovery setting as a means to reduce drug candidate attrition due to a lack of clinical efficacy. In particular, translational pharmacokinetic-pharmacodynamic (PK-PD) analysis has been used to help interpret and translate the results of preclinical studies (Salphati et al., 2010; Liu et al., 2011; Wong et al., 2012b,c; Yamazaki et al., 2012) . PK-PD modeling involves the use of differential equations to quantitatively describe drug behavior in the biologic system of interest. This type of analysis is particularly helpful in understanding concentration-effect relationships where there are apparent disconnects in drug concentration and effect related to temporal delays in drug action. In addition, mechanism-based PK-PD models allow for known species differences in factors such as PK or in vivo drug potency to be quantitatively assessed as well as enabling a more robust characterization of concentration-effect relationships from frequently variable in vivo preclinical efficacy data. Finally, establishment of PK-PD models enables better integration of available data and prospective simulations.
We have previously reported on the biologic characteristics, including the preclinical and clinical PK, of GDC-0152
, a potent pan-selective antagonist of IAP proteins ( Fig. 1) (Flygare et al., 2012) . GDC-0917
is a potent second-generation pan-selective IAP antagonist with binding affinities to the BIR3 domains of X-IAP and cIAP1/2, and the BIR domain of ML-IAP in the low nanomolar range (K i , 60 nM) using a fluorescence polarization-based competition assay. The previously undisclosed structure of GDC-0917 is shown in Fig. 1 . GDC-0917 caused a decrease in cell viability in MDA-MB-231 human breast cancer cells while having no effect on normal human mammary epithelial cells. In contrast to GDC-0152, which was administered intravenously, the intended route of administration of GDC-0917 is oral.
The objective of our study was to characterize the preclinical PK properties of GDC-0917. We show how learnings from a prototype molecule, GDC-0152, can be applied to a second-generation molecule, GDC-0917. In particular, we show how our prior knowledge of the disposition characteristics of GDC-0152 was leveraged to predict the human PK for GDC-0917. Furthermore, prospective human simulations were performed to determine the number of patient cohorts required to achieve the predicted human efficacious doses as a means to assess the feasibility of a human clinical trial. This study serves as an illustration of how mathematic modeling and simulation techniques can be used to provide an integrated preclinical assessment of a drug candidate and aid in the translation of preclinical data to the clinic.
Materials and Methods
Preclinical GDC-0917 In Vivo PK Studies in Rat, Mouse, Dog, and Monkey
The preclinical in vivo studies described in this article were conducted according to protocols approved by the Institutional Animal Care and Use Committee at Genentech (South San Francisco, CA).
Rat PK Study. Three male Sprague-Dawley rats (Charles River Laboratories, Hollister, CA) were given an intravenous (i.v.) dose of 1 mg/kg (freebase equivalent) of GDC-0917 trifluoroacetate salt (Genentech, Inc., South San Francisco, CA) in phosphate-buffered saline (PBS), via femoral vein cannulae. An additional three male rats were given a single oral (PO) dose of 5 mg/kg (free-base equivalent) of GDC-0917 trifluoacetate salt in PBS. At the initiation of the study, the rats weighed from 284 to 306 g.
Blood samples (;0.2 ml per sample) were collected from each animal via jugular vein cannulae at the following time points: predose and 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours postdose. All samples were collected into tubes containing potassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. Blood samples were centrifuged within 30 minutes of collection, and plasma was harvested. Plasma samples were stored at approximately -70°C until the analysis for GDC-0917 concentration via a liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay method.
Mouse PK Study. Twenty-seven female SCID.bg mice (Charles River Laboratories) were given an i.v. dose of 1 mg/kg of GDC-0917 in 15% hydroxypropylb-cyclodextrin and 20 mM succinic acid in water. An additional 27 female SCID.bg mice were given a single PO dose of 3 mg/kg of GDC-0917 in 0.5% w/v methylcellulose with 0.2% v/v Tween 80. The mice weighed from 17 to 20 g at the initiation of the study. Approximately 0.2 ml of blood was collected from each mouse by terminal cardiac puncture. Blood samples (n = 3 mice per time point) were taken from i.v. dosed mice at the following time points: predose and 0. 033, 0.17, 0.5, 1, 3, 6, 9 , and 24 hours postdose. Blood samples were collected from orally dosed mice at the following time points (n = 3 mice per time point): predose and 0. 083, 0.25, 0.5, 1, 3, 6, 9 , and 24 hours postdose. All blood samples were collected into tubes containing EDTA as an anticoagulant. Blood samples were centrifuged within 30 minutes of collection, and plasma was harvested. Plasma samples were stored at approximately -70°C until analysis for GDC-0917 via LC-MS/MS. Dog PK Study. Three male beagle dogs (Covance Laboratories, Cumberland, VA) were given a single i.v. dose of 1 mg/kg of GDC-0917 in 15% hydroxypropylb-cyclodextrin and 20 mM succinic acid in water. An additional three male beagle dogs (Marshall Bioresources, Beijing, China) were administered a PO dose of 1 mg/kg of GDC-0917 in 0.5% w/v methylcellulose with 0.2% v/v Tween 80. At the initiation of this study, dogs weighed from 9.2 to 12.5 kg.
Blood samples (;3 ml per sample) were collected from the peripheral vein of i.v. and PO animals at the following time points: predose and 0. 033, 0.083, 0.25, 0.5, 1, 3, 6, 9 , and 24 hours postdose. All blood samples were collected in tubes containing EDTA. Blood samples were centrifuged, and plasma was harvested within 1 hour of collection. Urine was collected from PO dogs into containers on wet ice during the following intervals: predose and from 0-8 and 8-24 hours postdose. Plasma and urine samples were stored at approximately 270°C until analysis for GDC-0917 via LC-MS/MS.
Monkey PK Study. Three male cynomolgus monkeys (Covance Laboratories, Madison, WI) were given a single i.v. dose of 1 mg/kg GDC-0917 in 15% hydroxypropyl-b-cyclodextrin and 20 mM succinic acid in water via a saphenous vein. An additional three male monkeys were given a PO dose of 2 mg/kg GDC-0917 in 0.5% w/v methylcellulose with 0.2% v/v Tween 80. At the initiation of this study, monkeys weighed from 2.1 to 2.6 kg.
Blood samples (;1 ml per sample) were collected from the femoral vein of each animal at the following time points after i.v. dosing: predose and 0. 033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 , and 24 hours postdose. After PO dosing, we collected blood samples at the following time points: predose and 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours postdose. All blood samples were collected into tubes containing EDTA.
The blood samples were centrifuged within 1 hour of collection, and plasma was harvested. Urine was collected from monkeys receiving the i.v. dose at predose and from 0-8 and 8-24 hours postdose in plastic containers surrounded by wet ice. Plasma and urine samples were stored at approximately 270°C until analysis for GDC-0917 via LC-MS/MS.
Human PK Study with GDC-0917
The human PK parameters were determined using data from a phase 1 doseescalation study in cancer patients using a modified continual reassessment method design. Institutional review boards at participating institutions approved the protocol for the phase 1 study. Written, informed consent was obtained from all trial participants.
Briefly, doses ranging from 5 to 600 mg of GDC-0917 were administered orally as a single dose to cancer patients. After a 3-day washout period, GDC-0917 was administered daily for 14 days. Plasma samples were collected at predetermined time points after the first dose (0, 0.5, 1, 2, 3, 6, 9, 24, 48, and 72 hours) and the last dose (0, 0.5, 1, 2, 3, 6, and 24 hours) for characterization of single-dose and steady-state PK. Plasma samples were stored at approximately 270°C until analysis for GDC-0917 concentrations via LC-MS/MS. The arithmetic mean concentration-time data are presented for three Caucasian female patients after a single oral 5-mg dose of GDC-0917. The three patients ranged from 36 to 56 years of age, and their weight ranged from 66 to 99 kg.
Blood was collected for PD marker (cIAP1) measurement at predose and 6 hours postdose after a single oral dose of GDC-0917. The cIAP1 protein concentrations in patient samples were determined by use of a cIAP1 immunoassay in peripheral blood mononuclear cells (PBMC), as will be described later. The cIAP1 levels in patient samples taken at 6 hours postdose are expressed as a percentage of predose cIAP1 levels.
PK Analysis
All PK parameters were calculated by noncompartmental methods as described in Gibaldi and Perrier (1982) using WinNonlin version 3.2 (Pharsight Corporation, Mountain View, CA). Parameters are presented as mean 6 S.D.
Prediction of Volume of Distribution by Allometric Scaling
Simple allometric scaling was used to predict human volume of distribution. In vivo volume of distribution at steady state (V ss ) estimates from preclinical PK studies were fit to the following log transformed form of the allometric equation (Boxenbaum, 1984) by linear regression:
where Y is the volume of distribution, a is the coefficient of the allometric equation, W is the body weight, and b is the allometric exponent. The predicted human volume of distribution was extrapolated using the fitted line and an assumed body weight of 70 kg.
Prediction of Hepatic Clearance Using Metabolic Stability Studies in Hepatocytes
The metabolic stability of GDC-0917 (1 mM) was determined in pooled (n = 5-10) human, rat, and dog cryopreserved primary hepatocytes (CellzDirect/ Invitrogen Corporation, Durham, NC). Incubations (final incubation volume 250 ml) were performed at 37°C under an atmosphere of 95/5 CO 2 /O 2 using 0.5 million cells/ml in hepatocyte incubation media (In Vitro Technologies, Baltimore, MD). We took 50-ml aliquots (cells and media) at 0, 1, 2, and 3 hours after the start of the incubation and quenched them using 100 ml ice-cold acetonitrile. The resulting samples were centrifuged at 3000g for 10 minutes. The supernatant (90 ml) was diluted in water (180 ml), and the percentage remaining of GDC-0917 was assessed by LC-MS/MS. All incubations were performed in triplicate. The intrinsic clearance was estimated from the percentage of GDC-0917 remaining versus the time plot using the standard methods described by Obach et al. (1997) . The intrinsic clearance was scaled to hepatic clearance using the "well-stirred" model by standard methods (Khojasteh et al., 2011) .
Prediction of Half-Life
Human half-life (t 1/2 ) was predicted using the following equation:
where CL is the predicted human hepatic clearance based on in vitro-in vivo extrapolation of hepatocyte metabolic stability studies with GDC-0917, and V ss is the predicted human volume of distribution using allometry (see section titled Prediction of Volume of Distribution by Allometric Scaling).
Antitumor Efficacy Studies in MDA-MB-231-X1.1 Xenograft Mice
Briefly, 10 million MDA-MB-231-X1.1 breast adenocarcinoma cells resuspended in Hank's balanced salt solution and Matrigel (1:1, v/v) were implanted subcutaneously into the upper right flank of female SCID.bg mice (Charles River Laboratories, Hollister, CA). MDA-MB-231-X1.1 cells are MDA-MB-231 cells (originally from the American Type Culture Collection [ATCC], Manassas, VA) that were selected for improved in vivo growth rates. When tumor volumes reached approximately 100-300 mm 3 , mice were assigned to treatment groups to get a similar mean tumor size for each treatment group. Treatment groups (n = 5 per group) were administered once daily oral doses of vehicle (15% hydroxypropyl-b-cyclodextrin, 20 mM succinic acid in water), 0.08, 0.17, 0.34, 0.68, 1.36, 2.72, 5.43, 10.87, or 16 .30 mg/kg of GDC-0917 for 21 days. Tumor volumes were measured in two dimensions (length and width) using Ultra Cal IV calipers (Model 54 10 111; Fred V. Fowler Company, Newton, MA). The following formula was used with Excel version 11.2 (Microsoft Corporation, Redmond, WA) to calculate tumor volume (TV): TV (mm 3 ) = (Length Â Width 2 ) Â 0.5. Tumor sizes and body weights were recorded twice weekly, and the mice were regularly observed over the course of the study. Mice were euthanized if their tumor volume exceeded 2000 mm 3 or if their body weight dropped by more than 20% of the starting weight.
A satellite group of female SCID.bg mice were given single oral doses of 0.5-20.0 mg/kg of GDC-0917 in 15% hydroxypropyl-b-cyclodextrin, 20 mM 2106 Wong et al. at ASPET Journals on October 14, 2017 dmd.aspetjournals.org succinic acid in water to provide an assessment of the oral PK of GDC-0917 to support the xenograft efficacy study. Blood was collected at 0.08, 0.25, 0.5, 1, 3, 6, 9, and 24 hours postdose, and plasma was harvested within 1 hour of blood collection. Plasma samples were frozen at approximately 280°C until analysis for GDC-0917 concentrations using LC-MS/MS.
Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
The PK-PD modeling was performed using SAAM II (Saam Institute, University of Washington, Seattle, WA).
Supporting Mouse PK Studies for PK-PD Modeling. Plasma concentrationtime data from female SCID.bg mice given 0.5-20 mg/kg GDC-0917 were simultaneously fitted to a one-compartment model with oral absorption. The PK of GDC-0917 appeared linear over the dose range tested. Mean estimates of the absorption rate constant (k a ), the elimination rate constant (k e ), and the apparent volume of distribution (V/F) from all dose groups were used to simulate GDC-0917 concentrations in the modeling of the MDA-MB-231-X1.1 xenograft efficacy studies.
MDA-MB-231.X1.1 Breast Cancer Xenograft Efficacy Studies. MDA-MB-231.X1.1 xenograft efficacy studies were fitted to an indirect response model (Mager et al., 2003) as described by the following differential equation.
where
) is defined as the tumor volume, t (hours) is time, k ng (h 21 ) is the net
) is the rate constant describing the antitumor effect of GDC-0917, K max (h 21 ) is the maximum value of K, C (mM) is the concentration of GDC-0917, and KC 50 (mM) is the GDC-0917 concentration where K is 50% of K max . Concentrations of GDC-0917 in mice were simulated based upon the PK parameters obtained from the supporting mouse PK studies described earlier. Mean tumor volumes for each dose group were used for fitting. PD parameters are presented as the estimate followed by the coefficient of variation in parentheses.
cIAP Immunoassay in PBMC
The purpose of this study was to establish a cIAP1 immunoassay in PBMC for use in the clinical trial. Whole blood was collected in eight 8-ml cell preparation tubes (Becton Dickinson, Franklin Lakes, NJ) containing sodium heparin from each donor. Blood was pooled and transferred to 14-ml tubes and incubated in the dark at room temperature for ;16 hours in the presence of the vehicle DMSO (dimethylsulfoxide) or 0.0001-10 mM of GDC-0917. After incubation, each blood sample was transferred back into a cell preparation tube, and PBMCs were harvested from blood after centrifugation as per manufacturer's instructions and washed in cold PBS. Next, resulting PBMC pellets were lysed in 100 ml 1Â cell extraction buffer (Invitrogen, Grand Island, NY) containing protease inhibitors (Roche, Basel, Switzerland). Lysates were transferred to 1.5-ml microfuge tubes and centrifuged at 13,000g for 10 minutes at 4°C. The total cellular protein concentration for each PBMC lysate was determined using a microbicinchoninic acid assay (Pierce Biotechnology, Rockford, IL). The cIAP1 concentration was determined using an internally developed qualified cIAP1 immunoassay described as follows.
The cIAP1 assay involved incubation of the PBMC sample for ;16 hours with a biotinylated goat anti-human cIAP1 polyclonal antibody (R&D Systems, Minneapolis, MN), and a ruthenium-labeled rat anti-human cIAP1 monoclonal antibody (Enzo Life Sciences, Farmingdale, NY) in assay diluent. Streptavidincoated plates were blocked for nonspecific binding using 3% bovine serum albumin in wash buffer (0.05% polysorbate-20 in PBS) for ;16 hours at 4°C. The blocked plate was washed 3 times with 200 ml assay wash buffer. The sample/antibody mixture was incubated with the blocked immunoassay plate for 90 minutes at room temperature. The assay plate was again washed 3 times in assay wash buffer before addition of a chemiluminescent substrate reactive with the ruthenium-labeled secondary anti-cIAP1 antibody. The cIAP1 concentration in test samples was determined from a four-parameter regression analysis of a standard curve based on the chemiluminescence signal in the immunoassay. The cIAP1 levels in the samples are expressed in this article as a percentage of the DMSO control.
The relationship between GDC-0917 concentrations and cIAP1 decrease was characterized by estimation of PD parameters obtained by fitting an inhibitory I max model to the data using GraphPad Prism version 4.02 (GraphPad Software, San Diego, CA) based on the following equation:
where I (%) is the cIAP1 level expressed as a percentage of the DMSO control, I initial (%) is the initial value of I, I max (%) is the maximum value of I, IC 50 (mM) is the concentration of GDC-0917 where I is 50% of I max , and C (mM) is the GDC-0917 concentration.
Human Simulations
Simulations of human PK were performed using a one-compartment model with oral absorption. Parameters used for human simulations were derived from the predicted human hepatic clearance from hepatocyte metabolic stability studies, and the predicted human volume of distribution from simple allometry. The absorption rate constant (1.72 h
21
) used for human simulations was obtained from modeling the dog oral PK concentration-time data using a one compartment model with oral absorption. Bioavailability was assumed to be 1 2 E where E is the hepatic extraction ratio determined with the hepatocyte data using standard methods (Khojasteh et al., 2011) .
The predicted human doses required for 50% (ED 50 ) and 90% (ED 90 ) inhibition of tumor growth were determined using eq. 3 and the PD parameters derived from MDA-MB-231-X1.1 xenograft efficacy studies. Concentrations of GDC-0917 driving the response for eq. 3 were simulated using a onecompartment model with oral absorption and the predicted human PK parameters described in the previous paragraph. Simulations were performed to the last day of dosing in the xenograft study (day 21), which was the time point at which inhibition of tumor growth was assessed. We chose not to correct for potential differences in plasma protein binding between the mouse and human in these simulations as the definitive plasma protein binding studies were not yet available when this analysis was performed. In addition, preliminary plasma protein binding data suggested that unbound fraction could be approximately 3-fold higher in humans (15% unbound) compared with the mouse (5% unbound). Therefore, not correcting for potential species differences in plasma protein binding would be considered the most conservative estimate of ED 50 and ED 90 doses in human.
Additional simulations were performed at the starting dose of 5 mg before the start of the phase 1 clinical trial. These simulations were performed using eq. 4 and the associated PD parameters estimated from the in vitro cIAP experiment with GDC-0917 in PBMCs. GDC-0917 concentrations driving the response in eq. 4 for this simulation were generated using a one-compartment model with oral absorption and the predicted human PK parameters for GDC-0917. The purpose of these simulations was to predict both the anticipated GDC-0917 concentration-time profile and the degree of PD marker (cIAP1) modulation that would be observed in the first cohort of patients. Finally, an assessment of the number of cohorts required to achieve human ED 50 and ED 90 doses was performed to provide an early assessment of clinical trial feasibility and duration.
Results
Pharmacokinetics of GDC-0917 in Rat, Mouse, Dog, and Monkey. Pharmacokinetics studies were conducted in the rat, mouse, dog, and cynomolgus monkey to characterize GDC-0917 PK in preclinical species. Figure 2 shows semilog plots of GDC-0917 plasma concentration versus time for the mouse, rat, dog, and monkey after intravenous and oral administration. Derived PK parameters for each species are presented in Table 1 . Because the GDC-0917 bloodplasma ratio was approximately 1 (0.9-1.0) in all species tested, the in vivo plasma clearance was considered equivalent to the hepatic clearance. GDC-0917 has low plasma clearance (;13% of hepatic Preclinical Modeling and Simulation of GDC-0917 2107 at ASPET Journals on October 14, 2017 dmd.aspetjournals.org blood flow; Davies and Morris, 1993 ) in mice at approximately 12 ml/ min/kg. It has moderate plasma clearance (;50% of hepatic blood flow) in rats and dogs at 27 and 15.3 ml/min/kg, respectively. In monkeys, GDC-0917 has high plasma clearance of 67.6 ml/min/kg (;160% of hepatic blood flow). The terminal half-life (t 1/2 ) ranged from 0.825 hours in monkeys to 6.12 hours in dogs. The volume of distribution at steady state (V ss ) was low to moderate in all species evaluated. With the exception of monkeys, where oral bioavailability was 16.8%, the oral bioavailability was high, ranging from 77.0% in rats to 97.0% in dogs. The renal clearance of GDC-0917 was assessed in dogs and monkeys and was found to be negligible, accounting for ,1% and approximately 2% of the plasma clearance, respectively. Predicted Human Clearance, Volume of Distribution, and HalfLife of GDC-0917. Hepatocyte metabolic stability studies were conducted in human, rat, and dog hepatocytes to predict the hepatic clearance in humans and to verify that an in vitro to in vivo correlation exists in rats and dogs. Table 2 presents the predicted hepatic clearance based on hepatocyte studies for rats, dogs, and humans along with the observed in vivo plasma clearance in rats and dogs. The predicted hepatic clearance for the rat and dog was within 2-fold of the observed in vivo plasma clearance for both species. Human hepatic clearance was predicted to be moderate at 11.5 ml/min/kg, and this value was used for subsequent human predictions and simulations.
Simple allometric scaling was performed to provide a predicted human volume of distribution of GDC-0917 (Fig. 3) . Estimates of the volume of distribution from the mouse, rat, dog, and monkey (Table 1) were used to predict a human volume of distribution of 6.69 l/kg (Fig. 3) . The predicted t 1/2 in humans based on the predicted volume of distribution and clearance was 6.70 hours.
MDA-MB-231-X1.1 Breast Cancer Xenograft Efficacy Studies. Antitumor efficacy studies were performed in mice xenografted with MDA-MB-231-X1.1 breast cancer cells to both demonstrate and characterize the antitumor activity of GDC-0917. Figure 4A presents a tumor volume versus time profile for a range of daily oral doses of GDC-0917 (0.08-16.3 mg/kg) given for 21 consecutive days. GDC-0917 antitumor activity was dose dependent with slight tumor regression observed at doses .5.43 mg/kg. GDC-0917 was well tolerated, with all dose groups experiencing a ,11% decrease in mean body weight.
Xenograft PK-PD Modeling and Simulation. Supporting mouse PK studies were conducted to provide PK information for PK-PD modeling of xenograft efficacy studies. Estimates of GDC-0917 PK parameters in the mouse after oral administration of 0.5, 3, 6, and 20 mg/kg in 15% hydroxypropyl-b-cyclodextrin, 20 mM succinic acid in water are as follows: k a = 17.6 h
21
, k e = 0.19 h
, and V/F = 1.74 l/kg. These PK parameters were used to simulate GDC-0917 concentrations when fitting tumor volume data from the xenograft efficacy study because it was not possible to collect blood from the xenografted mice that were studied. Figure 4B compares observed and predicted tumor volumes after simultaneous fitting of all MDA-MB-231-X1.1 tumor data to an indirect response model (eq. 3). In general, the indirect response model was able to adequately characterize the PK-PD relationship between GDC-0917 plasma concentrations and tumor volume growth inhibition. Estimated in vivo GDC-0917 PD parameters characterizing MDA-MB-231-X1.1 tumor growth and inhibition are presented in Table 3 .
Human Simulations Determining ED 50 and ED 90 Doses and Clinical Trial Feasibility. Human simulations were performed to predict GDC-0917 doses needed to achieve the ED 50 and ED 90 end points based on MDA-MB-231-X1.1 xenograft efficacy studies. These simulations were performed using the predicted human PK described previously and the PD parameters presented in Table 3 . In addition, the minimum number of cohorts required to reach the predicted ED 50 and ED 90 was assessed assuming a starting dose of 5 mg (derived from Fig. 3 . Predicted human volume of distribution using allometry. Table 3 and Fig. 5 . ED 50 and ED 90 doses in humans were predicted to be 72 mg and 660 mg, respectively. The predicted human concentration-time profile of the ED 50 and ED 90 doses and their associated AUC 0-24 are presented in Fig. 5B and Table 3 , respectively. Based on a traditional phase 1 oncology clinical trial design (Green et al., 2003) , and assuming no occurrence of doselimiting toxicities, a doubling of the GDC-0917 dose with each cohort, and a linear PK, we anticipate reaching ED 50 (72 mg) and ED 90 (660 mg) doses by cohorts 5 (80 mg) and cohort 8 (640 mg) (Fig. 5C ). Overall, these prospective simulations suggest that ED 50 and ED 90 are achievable in patients with acceptable doses and within an acceptable number of cohorts.
cIAP1 Immunoassay in PBMCs. A cIAP1 immunoassay in PBMCs was established and tested in vitro before the initiation of human clinical trials. Figure 6A presents the percentage decreases of cIAP1 relative to a DMSO control caused by GDC-0917 added to whole blood at concentrations ranging from 0.0001 to 10 mM. GDC-0917 induced reduction of cIAP1 levels in PBMCs in a concentrationdependent manner showing greater than 80% inhibition at concentrations greater than 0.1 mM (56.5 ng/ml) (Fig. 6A) . After fitting of the cIAP1 and GDC-0917 concentration data to an inhibitory I max model (eq. 4), PD parameters were estimated and are presented in Fig. 6B . Because the cIAP1 immunoassay involves the addition of GDC-0917 to whole blood before isolation of PBMCs, these PD parameters reflect the PD response to total blood concentrations rather than unbound.
Human Simulation of 5 mg Phase 1 Starting Dose. Simulations were performed before the start of the phase 1 clinical trial to predict both the anticipated GDC-0917 plasma concentration-time profile and the degree of cIAP1 modulation after the administration of a 5-mg starting dose to patients. These simulations used the predicted human PK and the PD parameters from the cIAP1 immunoassay in PBMCs (see Fig. 6B ). As shown in Fig. 7A and Table 4 , our prediction of human PK at the 5-mg dose of GDC-0917 agreed well with previously unpublished observations from the first cohort. Figure 7B presents a simulated cIAP1 response over a 24-hour period after administration of the 5-mg starting dose. Predicted cIAP1 levels at 6 hours postdose was approximately 32% of the predose level (Fig. 7B) . A mean cIAP1 decrease determined from two patient samples collected at 6 hours after the dose was comparable to the prediction, being 39% of predose levels (Fig. 7B) . dmd.aspetjournals.org
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Discussion
The preclinical PK and drug metabolism properties of a drug candidate often serve as an early assessment of its potential to succeed as a drug. However, the amount of information available in the early stages of the drug development process is often limited as preclinical studies are, out of necessity, performed in a staged format. Furthermore, the ability to translate preclinical findings to humans remains a challenge. GDC-0917 is a second-generation IAP antagonist that offers the advantage of oral dosing over our prototype molecule GDC-0152, which was administered intravenously once every 2 weeks. Also, GDC-0917 preclinical toxicology studies enabled continuous daily dosing, allowing for a more flexible choice of dosing regimen in the clinic.
Previously, we described the application of a toxicokinetictoxicodynamic (TK-TD) analysis of GDC-0152 rat and dog toxicology studies (Wong et al., 2012a) . We learned from this analysis that dogs were much more sensitive to IAP antagonists than rats, and we confirmed a lower sensitivity in humans using clinical data. The described analysis de-risked preclinical toxicity concerns around IAP proteins as drug targets, thereby enabling the advancement of a second-generation IAP antagonist. The current work describes the integration of preclinical modeling and simulation and the learn-and-confirm paradigm in the drug discovery process. We describe how we leveraged our understanding of GDC-0152 to predict human PK for GDC-0917. In addition, we show how preclinical modeling and simulation were used in the selection of GDC-0917 as a clinical candidate.
Based on previous work with GDC-0152 (Flygare et al., 2012; Yue et al., 2013) , we anticipated that the structurally similar GDC-0917 would be eliminated mostly by hepatic metabolism and that renal elimination of the compound would be limited. The low estimated renal clearance of GDC-0917 in the dog and monkey (Table 1) is consistent with these expectations. GDC-0152 human clearance was predicted using both simple allometry and in vitro-in vivo extrapolation (Flygare et al., 2012) . Both methods gave similar estimates of human clearance (9.6 ml/min/kg [allometry] and 10 ml/min/kg [in vitro-in vivo extrapolation]) and were successful in predicting observed clearance in patients (9 ml/min/kg). GDC-0152 volume of distribution was predicted using simple allometry (1.2 l/kg) and again the prediction matched well with clinical observations (0.6 l/kg) being within an acceptable 2-fold of the observed value (Flygare et al., 2012) .
Allometric methods for prediction of human clearance assume a relationship between clearance and body weight. For compounds where clearance is due to elimination dictated by physiologic processes such as blood flow or filtration, allometric methods work reasonably well (Lin, 1995) . Therefore, for high clearance compounds where clearance is blood-flow dependent and compounds that are cleared primarily via the urinary route, allometry is anticipated to perform reasonably well. However, the rationale of using allometric scaling for human PK prediction has been controversial (Bonate and Howard, 2000) , and a known shortcoming of using in vivo allometric dmd.aspetjournals.org methods is when there are known species differences in metabolism. As such, we consciously decided to use in vitro-in vivo extrapolation of metabolic stability data from human hepatocytes to predict human clearance for GDC-0917, providing that a reasonable in vitro to in vivo correlation could be established in preclinical species.
GDC-0917 showed good preclinical PK properties having low to moderate plasma clearance in all species with the exception of the monkey, which exhibited high clearance. The two primary preclinical species used to screen PK during compound optimization were the rat and dog. Therefore, early on, we performed metabolic stability studies in hepatocytes from these two preclinical species and human. The in vitro hepatocyte data were used to estimate hepatic clearance in rats, dogs, and humans. A good in vitro to in vivo correlation was observed in the rat and dog because the predicted hepatic clearance and the observed in vivo clearance were within 2-fold of each other (Table 2) . With a good in vitro to in vivo correlation established using the rat and dog, and no evidence of renal elimination being a major route of GDC-0917 elimination (Table 1) , human hepatic clearance was predicted to be moderate (11.5 ml/min/kg) using in vitro-in vivo extrapolation of human hepatocyte data. Similar to GDC-0152, simple allometry was used to predict human volume of distribution (i.e., 6.69 l/kg) (Fig. 3) . This prediction included the volume of distribution from all preclinical species, including the monkey, which was gathered at a later point in the compound evaluation process. Based on the predicted human clearance and volume of distribution, GDC-0917 halflife in humans was estimated to be 6.70 hours.
PK-PD modeling offers a means to improve the translation of preclinical studies to humans (Wong et al., 2012b, c; Yamazaki et al., 2012) . Tumor xenografted mice serve as a "workhorse" efficacy model to assess antitumor effects of novel agents and thus are widely used in oncology drug discovery (Johnson et al., 2001; Kelland, 2004; Peterson and Houghton, 2004; Wong et al., 2012b) . Our previous investigation showed that a correlation exists between antitumor activity in xenografted/allografted mice and clinical response, provided that two conditions were fulfilled. These conditions were 1) that species differences in mouse and human PK had to be normalized, and 2) that the specific xenograft model used in the assessment had to be relevant to human disease being treated (Wong et al., 2012b) . At the time of our work with GDC-0917, we arbitrarily set ED 50 and ED 90 as two efficacy end points from which we would evaluate the compound in a breast cancer model.
Fitting of the indirect response model (eq. 3) to tumor volume data from MDA-MB-231-X1.1 xenografted mice allowed us to define the relationship between GDC-0917 plasma concentrations and the antitumor effect. This relationship is characterized by the PD parameters K max (the maximum value of rate constant describing the antitumor effect of GDC-0917) and KC 50 (GDC-0917 concentration where K is 50% of K max ). Based on comparable estimates of K max to the net growth rate constant (k ng ), the maximum antitumor effect of GDC-0917 in MDA-MB-231-X1.1 xenografted mice is near tumor stasis. This is evident upon examination of the tumor volume versus time plot shown in Fig. 4A . In particular, at the high dose levels, increases in dose result in very little additional activity beyond tumor stasis.
Pharmacodynamic parameters estimated from xenografted mice were fixed and simulations were performed to identify ED 50 and ED 90 doses in humans using the predicted human PK ( Fig. 5 ; Table 3 ). The predicted ED 50 (72 mg) and ED 90 (660 mg) doses for humans were within an acceptable dose load for an oncology indication. Assuming a starting dose of 5 mg in patients, ED 50 and ED 90 could be reached within 5 to 8 cohorts, respectively (Fig. 5C ), suggesting that these end points could be achievable within an acceptable time frame of approximately 1 to 2 years based on normal enrollment rates (;3 months per patient cohort).
The final activity after the learn phase of our preclinical modeling and simulation exercise was to confirm our predictions upon receiving the patient data. Based on the predicted GDC-0917 PK and PD at the 5-mg starting dose, we anticipated observing some degree of PD biomarker (cIAP1) modulation in the first patient cohort. As shown in Fig. 7 , our simulations were consistent with previously unpublished clinical observations of PK (Fig. 7A) and PD (Fig. 7B ) in cancer patients who were given 5 mg of GDC-0917. These simulations served to increase confidence in our prospective simulations and to illustrate the value of confirming predictions upon receipt of human data.
Overall, the preclinical PK of GDC-0917 is favorable. The compound exhibits low to moderate in vivo clearance in all species other than the monkey, and it has good oral bioavailability. Based on our translational PK-PD analysis, ED 50 and ED 90 are achievable in humans at acceptable doses and within a reasonable time frame. Our experience with GDC-0917 shows the importance of leveraging learnings from prototype molecules when advancing secondgeneration molecules. Finally, our work with GDC-0917 illustrates how implementation of modeling and simulation techniques and the learn-and-confirm paradigm into the early phases of the drug development process can add value by integrating existing preclinical data and aid in its translation to the clinic. 
